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ORIGINAL RESEARCH 
Background: In an early study of highly symptomatic patients with PI*Z alpha-1 antitrypsin 
deﬁ  ciency (AAT), tobacco smoking was identiﬁ  ed as a risk factor by comparing the age of 
symptom onset in smokers and nonsmokers. Age of symptom onset has not been well studied 
in relationship to other environmental exposures.
Methods: Environmental exposures were assessed in 313 PI*Z adults through retrospective 
self-administered questionnaire. Age of onset of symptoms with and without these exposures 
were analyzed through survival analysis.
Results: Personal smoking was the most important risk factor, associated with earlier onset 
of cough and wheeze, and showed a dose-dependent relationship with the onset of dyspnea. 
Childhood environmental tobacco smoke (ETS) exposure was independently associated with 
younger age of onset of cough. Earlier onset of wheeze was also associated with childhood 
respiratory infections and family history of emphysema. The report of childhood respiratory 
infections was associated with childhood ETS exposure, but no statistically signiﬁ  cant interac-
tions were noted.
Conclusions: We conclude that both personal and secondhand exposure to tobacco smoke in 
childhood are likely to accelerate the onset of symptoms in AAT deﬁ  cient patients. Respiratory 
infections in childhood may also contribute to this risk.
Keywords: alpha-1 antitrypsin deﬁ  ciency, tobacco smoke pollution, respiratory symptoms, 
lower respiratory illness.
Introduction
PI*Z individuals have a severe deﬁ  ciency of alpha-1 antitrypsin (AAT) and are geneti-
cally susceptible to developing chronic obstructive pulmonary disease (COPD) (Black 
and Kueppers 1978; Larsson, 1978; Tobin et al 1983; Janus et al 1985; Brantly et al 
1988; Silverman et al 1989) particularly with personal tobacco use (Larsson 1978; 
Tobin et al 1983; Janus et al 1985; Brantly et al 1988; Silverman et al 1989). Other 
reported risk factors include occupational exposures (Piitulainen et al 1997, 1998; 
Mayer et al 2000b), lower respiratory tract infections (Brantly et al 1988; Silverman 
et al 1989), and family history of emphysema (Silverman et al 1989). In an early study 
of highly symptomatic PI*Z patients, tobacco smoking was identiﬁ  ed as a risk factor 
by comparing the age of symptom onset in smokers and nonsmokers (Larsson 1978). 
Age of symptom onset has not been well studied in relationship to other exposures.
Childhood environmental tobacco smoke (ETS) exposure has been associated with 
increased frequency and severity of respiratory infections (Colley et al 1974; Ware 
et al 1984; Fergusson and Horwood 1985; Tager et al 1993; Chen 1994; Strachan and 
Cook 1997), respiratory symptoms (Cunningham et al 1996; Ehrlich et al 1996; Jaak-
kola et al 1996; Withers et al 1998), and diminished airﬂ  ow (Ware et al 1984; Tager 
et al 1993) in the general population. A prospective study of PI*Z children found a 
greater prevalence of recurrent wheezing at 4 years of age in those with two smoking 
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parents. Lower forced expiratory volume in one second 
[FEV1]/forced vital capacity [FVC] ratio was found in that 
group at 18 years, although no difference in FEV1 or wheeze 
was seen (Piitulainen and Sveger 1998). Childhood lower 
respiratory infections have been associated with respiratory 
symptoms (Gold et al 1989) and airﬂ  ow limitation (Gold 
et al 1989; Shaheen et al 1994; Johnston et al 1998) in the 
general population. An interaction between the effects of 
ETS exposure and respiratory infections has been postulated 
(Gold et al 1989; Strachan and Cook 1997).
We systematically surveyed 313 PI*Z individuals to 
examine the relationships of personal tobacco use, child-
hood ETS exposure, and respiratory infections to age of 
symptom onset.
Methods
Study subjects
The study protocol was approved by the Human Subjects 
Institutional Review Board of the National Jewish Medical 
and Research Center. A total of 329 subjects self-reporting 
PI*Z phenotype were recruited from four sources. Sixty-two 
were recruited through a national educational meeting on 
AAT deﬁ  ciency (Group 1), 94 from two different outpatient 
clinics specializing in AAT deﬁ  ciency (Groups 2 and 3), 
and 173 through mailings sent out through a national AAT 
registry (Group 4). The participation rate was 75% in the 
ﬁ  rst two groups. To maintain conﬁ  dentiality, individuals in 
Groups 3 and 4 were invited to participate by the other clinic 
and by the registry themselves, respectively. We do not know 
how many of these individuals in these two groups chose not 
to participate. Exclusion criteria were age less than 30 years 
and diagnosis of lung cancer.
Survey instrument
The study instrument was a self-administered questionnaire 
designed for a larger study on occupational and environ-
mental exposures (Mayer et al 2000b). Childhood ETS was 
assessed by the question “Did you live or work with someone 
who smoked every day during childhood (age 0–18 years)”, 
and if so, “For how many years” and “Year of last expo-
sure”. Participants were considered to have had childhood 
ETS exposure if they reported 12 or more years of exposure 
and/or we could verify that they were exposed for the ﬁ  rst 6 
years of life by comparing the year of birth and the year of 
last exposure. Personal tobacco use was assessed through 
standardized American Thoracic Society (ATS) questions 
(Davis et al 1978). The number of pack-years smoked before 
the development of each symptom was calculated. If the indi-
vidual never developed the symptom, the lifetime number of 
pack-years was used. Those who reported an age of beginning 
smoking after the reported age of symptom development were 
considered to have smoked 0 pack-years, as were the never-
smokers. Smokers were grouped by number of pack-years 
smoked before the development of each symptom: 1–10, 
11–20, 21–30, and greater than 30 pack-years. Those with 0 
pack-years served as the referent group. Childhood respira-
tory infection was deﬁ  ned as either pneumonia or recurrent 
episodes of bronchitis reported in childhood. Family history 
of emphysema was determined by indication that at least one 
parent had emphysema.
Symptoms of cough and wheeze were based on questions 
modiﬁ  ed from the ATS-DLD-78 questionnaire (Davis et al 
1978). Chronic cough was deﬁ  ned as cough 4–6 times per day 
or night almost every day, or daily morning cough present 3 
or more months per year. Wheeze was deﬁ  ned as “wheeze oc-
casionally, apart from colds.” A dyspnea scale modiﬁ  ed from 
the St. George’s questionnaire (Jones et al 1992) was used to 
assess current dyspnea, deﬁ  ned as “breathlessness walking 
outside, on level ground at your own pace.” Age of symptom 
onset was assessed in individuals with current symptoms 
through the question: “How old were you when you ﬁ  rst 
started to notice (this symptom) on a regular basis?”
Statistics
Survival analyses were performed using Cox proportional 
hazards modeling (Elashoff 1983). The hazard rate may 
be thought of as the instantaneous odds of developing the 
symptom at a given age for those individuals who have not 
developed that symptom before that age. The hazard ratio 
(HR) is the hazard rate for those in the risk group divided 
by the hazard rate for those not in the risk group. A separate 
Cox model was created for outcomes of cough, wheeze, and 
dyspnea onset. Models were created using only one predic-
tor variable at a time, as well as multivariable modeling of 
the predictor variables of pack-years of smoking before the 
development of each symptom, childhood ETS, childhood res-
piratory infections, and family history of emphysema. Three 
sets of interaction were also examined in these models. First, 
exposure variable by age of onset of symptom interactions 
were included to test for the proportional hazards assumption, 
ie, that the HR does not vary by age of symptom onset. Plots 
of differences in log cumulative hazard rates for the exposure 
group versus age of onset of symptom were also examined to 
determine if simple interaction terms were adequate to account International Journal of COPD 2007:1(4) 487
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for nonproportional hazards. Second, group by exposure 
variables were included to test for heterogeneity between 
sampling groups. None of these group interaction terms were 
signiﬁ  cant. Third, exposure interactions were also examined. 
The main interaction of interest here was between ETS and 
respiratory infections, controlled for personal smoking. Inter-
actions between personal smoking and respiratory infections, 
ETS and personal smoking, ETS and family history, and fam-
ily history and personal smoking were also examined. None 
of these interactions reached a signiﬁ  cance level of <0.1 in 
the ﬁ  nal model, so results are not presented here.
Odds ratios of current symptoms and of respiratory infec-
tions given childhood ETS exposure were estimated using 
logistic regression techniques and chi-square test. Spearman 
correlation coefﬁ  cients were used to assess the association 
between the ages of onset of cough, wheeze, and dyspnea. 
Differences between groups were assessed by ANOVA. All 
statistical tests were two-sided and were considered statisti-
cally signiﬁ  cant at the 5% level. Statistical analyses were 
performed using JMP (version 3.2, SAS Institute Inc., Cary, 
NC) and SAS (version 6.12, SAS Institute Inc.).
Results
Demographics and prevalence of 
exposure
The mean age of the participants was 52.9 years and 54% were 
male. Seventy-one percent (n = 223) reported childhood ETS 
exposure (Table 1). Sixteen individuals were excluded from 
the analysis due to uncertainty of ETS exposure. Seventy-four 
percent of subjects reported they had smoked cigarettes, pipes, 
or cigars. Only two individuals continued to smoke. Forty-two 
percent of subjects reported having had recurrent bronchitis 
and/or pneumonia in childhood. The effects of education and 
smoking could not be separated, as all of the participants with 
less than a high school degree were ever-smokers.
Baseline characteristics of the participants in the four 
recruitment groups are shown in Table 2.
We compared the prevalence of exposure and outcome 
measures between the four groups. There were no signiﬁ  cant 
differences, other than participants from Group 1 tended to 
report an earlier age of onset of symptoms, and this was statis-
tically signiﬁ  cant for cough, although Group 1 did not report 
more current symptoms. PI*Z phenotype was self-reported. 
The phenotype was veriﬁ  ed in 89 of the 128 participants of 
Groups 1 and 2 (70%). All veriﬁ  ed individuals were PI*Z, 
except for one PI*SZ individual.
Individuals with childhood ETS exposure differed in 
their personal tobacco use from those without ETS exposure 
(Table 1). Those who were exposed to childhood ETS were 
more likely to become smokers themselves (77% vs 66%, 
p = 0.031). They were also more likely to begin smoking at 
an earlier age (16.6 years vs 18.4, p < 0.001). There was no 
difference in the intensity of smoking (19.4 vs 18.7 cigarettes 
per day, p = 0.279).
Age of onset of symptoms
Our study population was relatively symptomatic with 47% 
reporting chronic cough, 69% reporting wheeze, and 49% 
Table 1 Baseline characteristics of 313 individuals with PI*Z alpha-1 antitrypsin deﬁ  ciency according to presence or absence of 
childhood ETS exposure
Variable  With childhood ETS  Without childhood  p-value
  exposure (n = 223)  ETS (n = 90)
Age (mean years ± SD)  52 ± 10  55 ± 11  0.057
Gender (male)  53%  61%  0.185
Ever smokers  77%  66%  0.031
Mean number of cigarettes smoked  19.4 ± 8.7  18.7 ± 9.4  0.617
per day (in ever smokers)
Mean age of beginning smoking
(mean years ± SD)  16.6 ± 0.3 18.4  ± 0.5 <0.001
History of prior lower respiratory tract infection  41%  44%  0.634
Family history of emphysema  49%  23%  <0.001
Chronic cough  50%  39%  0.081
Chronic wheeze  71%  66%  0.361
Chronic dyspnea  50%  47%  0.618
Abbreviations: ETS, environmental tobacco smoke; SD, standard deviation.
Note: Bold indicates statistical signiﬁ  cance.International Journal of COPD 2007:1(4) 488
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reporting dyspnea. In those who reported current symptoms, 
the mean age of onset of cough was 37 years, 39 years for 
wheeze, and 41 years for dyspnea. Ages of symptom onset 
were highly correlated (all p < 0.05): r = 0.79 for wheeze and 
dyspnea, r = 0.71 for cough and breathlessness, and r = 0.69 
for cough and wheeze. In those who developed a symptom, 
the mean age of onset was 11 years earlier in smokers for 
cough (35 years ± 13 vs 46 ± 17, p < 0.001), 5 years earlier 
for wheeze (38 years ± 12 vs 43 ± 20, p = 0.041), and eight 
years earlier for dyspnea (39 years ± 10 vs 47 ± 17, p < 0.001) 
with greater variability seen in the never smokers (Table 3). 
Only onset of cough was earlier in the never-smokers with 
ETS exposure. Childhood respiratory infections were signiﬁ  -
cantly associated with earlier onset of all symptoms in both 
never-smokers and smokers. The odds of currently having 
each symptom by exposure are shown in Table 4. Results 
of the Cox proportional hazards modeling for developing 
symptoms are shown in Table 5.
The onset of cough and wheeze was earlier in smokers 
compared with never-smokers, with the greatest effect seen 
in those smoking 1 to 10 pack-years (HR = 2.16, 95% conﬁ  -
dence interval [CI] = 1.18–3.96) and (HR = 1.90; 95% CI = 
1.10–3.30) respectively. Earlier onset of dyspnea was seen in 
those smoking more than 10 pack-years with the greatest risk 
between 20–30 pack-years (HR = 2.71; 95% CI = 1.48–4.97). 
Family history of emphysema was associated with earlier on-
set of wheeze (HR = 1.72; 95% CI = 1.20–2.47), but did not 
remain signiﬁ  cant in the ﬁ  nal model for cough or dyspnea.
Table 2 Baseline characteristics of 313 individuals with PI*Z alpha-1 antitrypsin deﬁ  ciency by recruitment group
Comparison of characteristics between groups  Group 1  Group 2  Group 3  Group 4  p-value
Age (mean years ± SD)  51.4 ± 9.4  51.4 ± 1.26  53.4 ± 12.0  53.9 ± 10.5  0.232
Gender  (male)  56%  54% 50% 54% 0.956
Ever smokers  80%  69%  65%  74%  0.362
Mean number of cigarettes smoked per day (in ever smokers)  19.9 ± 10.1  17.4 ± 7.9  18.8 ± 10.5  19.8 ± 8.4  0.441
Mean age of beginning smoking (mean years ± SD)  17.1 ± 3.1  17.3 ± 2.8  16.9 ± 2.8  17.1 ± 3.8  0.976
Childhood ETS exposure  69%  69%  75%  72%  0.903
History of prior lower respiratory tract infection  54%  38%  31%  41%  0.206
Family history of emphysema  35%  48%  26%  40%  0.283
Chronic  cough  59%  56% 50% 50% 0.609
Chronic  wheeze  74%  68% 73% 67% 0.716
Chronic  dyspnea  53%  62% 42% 53% 0.151
Mean age of onset of cough  32.6 ± 11.8  35.1 ± 14.9  41.0 ± 13.7  39.7 ± 14.6  0.039
Mean age of onset of wheeze  36.4 ± 12.8  39.0 ± 13.6  39.7 ± 20.1  40.6 ± 14.5  0.388
Mean age of onset of dyspnea  37.2 ± 10.4  39.2 ± 12.6  41.4 ± 15.1  42.2 ± 12.6  0.061
Abbreviations: ETS, environmental tobacco smoke; SD, standard deviation.
Note: Bold indicates statistical signiﬁ  cance.
Table 3 Mean age of symptom onset for childhood ETS exposure, childhood lower respiratory infections, personal smoking, 
and family history of emphysema
 Cough    Wheeze    Dyspnea
  Smoker  Never smoker  Smoker  Never smoker  Smoker  Never smoker
Smoking status alone  46 ± 17  36 ± 13  43 ± 20  38 ± 12  47 ± 17  39 ± 10
   (<0.001)   (0.041)   (<0.001)
With/without  42/53 ±   34/39 ±   42/44 ±   37/42 ±   47/47 ±   37/43 ±
childhood ETS 15/±  11  12/± 14  19/± 20 12/±  12  18/±16 10/±9
  (0.043) (0.061)  (0.827)  (0.003) (0.940)  (0.001)
With/without childhood  36/49 ±   32/37 ±   35/40 ±   32/38 ±   39/49 ±   36/39 ± 
respiratory infections  19/± 13  11/± 13  14/± 11  23/± 17  21/±14  10/±9
  (0.011) (0.040)  (0.018) (0.018)  (0.013) (0.045)
With/without  44/49 ±   33/37 ±   41/43 ±   36/39 ±   45/48 ±   38/40 ± 
family history  17/± 16)  12/± 12)  18/± 23  12/± 12  9/±10  10/±9
  (0.386) (0.049)  (0.731) (0.058)  (0.808) (0.137)
Abbreviations: ETS, environmental tobacco smoke; SD, standard deviation.
Note: Bold indicates statistical signiﬁ  cance.
Mean age of onset 
of symptom ± SD 
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In crude analyses, those with childhood ETS exposure 
had earlier onset of cough in a nonproportional manner, such 
that the increased risk seen age at 20 (HR = 2.78, p = 0.012) 
gradually diminished by age 45 compared with those with-
out childhood ETS. Earlier onset of wheeze was of border-
line signiﬁ  cance (HR = 1.34; p = 0.058). No increased risk 
was seen for dyspnea (HR = 1.38, p = 0.077). In the Cox 
proportional hazards model, ETS continued to be associ-
ated with earlier age of onset of cough only (HR = 2.11; 
95% CI 1.18–3.76). All of the crude analyses for childhood 
respiratory infections were nonproportional. Risk of earlier 
onset of cough (HR = 1.98, p = 0.024 at age 20) dimin-
ished by age 35, wheeze (HR = 2.67, p = 0.001 at age 20) 
diminished by age 45, and dyspnea (HR = 2.83, p = 0.016 
at age 20) diminished by age 40. In the Cox proportional 
hazards model, childhood respiratory infections continued 
to be associated only with earlier onset of wheeze (HR = 
1.49; 95% CI = 1.05–2.11.)
Those with childhood ETS exposure were more likely to 
report respiratory infections in childhood (HR = 1.57; 95% 
CI = 1.00–4.45). In the Cox proportional hazards modeling, 
there were no signiﬁ  cant interactions between childhood 
ETS exposure and respiratory infections on age of symptom 
onset; the largest (HR = 1.96, 95% CI = 0.80–4.83) was seen 
for onset of dyspnea.
Discussion
In this study, we found that childhood ETS exposure was as-
sociated with earlier onset of cough in individuals with PI*Z 
AAT deﬁ  ciency. Childhood respiratory infections and family 
history were associated with earlier onset of wheeze. Among 
those with symptoms, childhood respiratory infections were 
associated with earlier onset of all symptoms in both smokers 
and never-smokers. With personal smoking, increased risk of 
onset of cough and wheeze was noted within the ﬁ  rst 10 pack-
years. Earlier onset of dyspnea was seen after 10 pack-years 
with a dose-dependent increased risk up to 30 pack-years.
In an earlier analysis of Groups 1 and 2, we had found a 
statistically signiﬁ  cant association between childhood ETS 
exposure and earlier age of onset of cough, wheeze, and 
dyspnea, adjusted for personal smoking, dichotomized as 
ever- or never-smoker (Mayer et al 2000a). The main reason 
for recruiting additional subjects for this second study was to 
increase sample size. We also realized that we had the ability 
to calculate the number of pack-years smoked before the age 
on onset of symptoms, thus giving a better measure of the 
“dose” of personal smoking. We had previously analyzed 
earlier age of beginning personal smoking in Groups 1 and 2, 
but we did not ﬁ  nd this to be a better or additive predictor. 
Although there was no overall difference in the number of 
cigarettes smoked per day between those with and without 
Table 4 Odds ratios of current symptoms for childhood ETS exposure, childhood lower respiratory infections, personal smoking, 
and family history of emphysema
Symptom  Childhood ETS  Ever Smoker  Childhood respiratory   Family history of 
     infections  emphysema
Cough 1.56  (0.94–2.57)  1.78 (1.18–2.94) 1.12  (0.67–1.84)  1.00  (0.62–1.61)
Wheeze 1.28  (0.76–2.15)  2.64 (1.59–4.41)  2.05 (1.21–3.51)  2.03 (1.11–3.21)
Dyspnea 1.13  (0.69–1.85)  2.28 (1.37–3.79) 1.63  (1.00–2.66)  1.03 (0.60–1.49)
Abbreviations: ETS, environmental tobacco smoke.
Note: Bold indicates statistical signiﬁ  cance.
Table 5 Adjusted hazard ratios for the development of symptoms for childhood ETS exposure, childhood lower respiratory 
infections, pack-years of smoking before onset of symptoms, and family history of emphysema
Risk factor  Cough  Wheeze  Dyspnea
Childhood ETS  2.11 (1.18–3.76)  1.26 (0.83–1.92)  1.00 (0.62–1.59)
Pack-years: 1–10  2.16 (1.18–3.96)  1.90 (1.10–3.30)  1.29 (0.63–2.60)
Pack-years: 11–20  1.00 (0.50–2.00)  1.51 (0.91–2.49)  2.35 (1.34–4.12)
Pack-years: 21–30  1.19 (0.63–2.24)  1.61 (0.98–2.65)  2.71 (1.48–4.97)
Pack-years: >30  1.23 (0.58–2.61)  1.15 (0.62–2.13)  2.20 (1.14–4.21)
Family history  1.26 (0.81–1.98)  1.72 (1.20–2.47)  1.30 (0.85–2.15)
Childhood respiratory infections  1.30 (0.84–1.99)  1.49 (1.05–2.11)  1.45 (0.97–1.98)
Abbreviations: ETS, environmental tobacco smoke.
Note: Bold indicates statistical signiﬁ  cance.International Journal of COPD 2007:1(4) 490
Mayer et al
childhood ETS, it is possible that these who began smoking 
earlier also smoked more intensely. A post-hoc analysis re-
vealed this trend (p = 0.079). We continued to see a greater 
association between childhood ETS and age of onset of 
wheeze and breathlessness in Groups 1 and 2 than in Groups 
3 and 4, albeit of borderline signiﬁ  cance. It is possible that 
the earlier reported age of onset of cough and breathlessness 
could have been contributory, but our analyses for heteroge-
neity did not reveal any statistically signiﬁ  cant differences 
between the groups.
No statistically signiﬁ  cant interactive effect on age 
of symptom onset was observed between the occurrence 
of childhood respiratory infections and ETS exposure. 
It is possible that the sample size conferred inadequate 
power to detect such an interaction. While we were able 
to identify those with ETS exposure in early childhood, 
we lacked information regarding the age at which lower 
respiratory tract infections occurred, precluding us from 
conﬁ  rming other observations (Colley et al 1974; Ware 
et al 1984; Fergusson and Horwood 1985) that childhood 
ETS exposure predisposes to infections during the ﬁ  rst few 
years of life. The questionnaire did not distinguish between 
prenatal, postnatal maternal, or paternal smoking. There 
remains considerable controversy regarding the relative risk 
conferred by these different exposure sources (Ware et al 
1984; Fergusson and Horwood 1985; Tager et al 1993; Chen 
1994; Strachan and Cook 1997). Because of our relatively 
small sample size, we combined bronchitis and pneumonia 
in childhood, but these may confer differential risk. As in-
dividuals reporting ETS exposure were more likely to also 
report previous lower respiratory tract infections, these risk 
factors would be additive in those individuals.
Experimentally, it takes time for the AAT deﬁ  ciency-
associated pulmonary parenchymal destruction to occur 
(Karlinsky and Snider 1978), which is supported by the 
observation in epidemiologic studies that few individuals 
develop symptoms before age 25 (Larsson 1978; Brantly 
et al 1988; Silverman et al 1989). It is possible that our 
study participants with current chronic symptoms may have 
reported respiratory symptoms in childhood that had nothing 
to do with their genetic disease. Even if they had, a serious 
detriment to quality of life is posed by the presence of res-
piratory symptoms during childhood and teenage years in 
a population at increased risk for an adult life with chronic 
progressive pulmonary problems.
While we examined the effects of prior respiratory 
infections and personal tobacco use, there may have been 
additional effects from other unmeasured exposures or host 
factors. For example, increased risk of airﬂ  ow limitation and 
chronic bronchitis has been found in smoking ﬁ  rst-degree 
relatives of individuals with severe COPD without AAT 
deﬁ  ciency (Silverman et al 1998).
Misclassiﬁ  cation and recall bias may have affected our 
results. It is possible that subjects reporting childhood ETS 
exposure may have been more likely to recall symptoms and 
to ascribe them to an earlier age. However, the 6% of subjects 
reporting dyspnea before age 20 in this series is similar to the 
7% with symptoms before age 20 in the study by Brantly and 
colleagues (1988), but less than the 18% reporting lung trou-
ble before age 16 in the series by Silverman and colleagues 
(1989), making it less likely that our subjects signiﬁ  cantly 
underestimated their age of onset of symptoms. We may 
have missed signiﬁ  cant childhood ETS exposure outside of 
the home, biasing our results towards the null. Alternatively, 
individuals with earlier onset of symptoms may have been 
more likely to report childhood ETS exposure. This would 
have led to a selective misclassiﬁ  cation of exposure, falsely 
implicating childhood ETS exposure or increasing the mag-
nitude of its true effect. We attempted to minimize this bias 
by separating these two questions and nesting them among 
questions about other current symptoms and environmental 
exposures, respectively. As there was no real association 
between childhood ETS exposure and current symptoms, we 
do not believe current clinical status presented a signiﬁ  cant 
source of bias.
Although we adjusted for personal tobacco use in the 
Cox proportional hazards modeling, it is possible that some 
confounding still occurred. Never-smokers may have had 
a greater tendency to recall ETS exposure than smokers. 
A “healthy smoker effect” is possible whereby those who 
chose never to smoke may somehow already have been less 
healthy than those who did. It is also possible that the ef-
fects of personal tobacco use outweighed and obscured the 
effects of childhood ETS exposure. The mean age of smok-
ing commencement was almost 2 years earlier in those with 
ETS exposure compared with those without exposure. It is 
likely the signiﬁ  cantly earlier age of onset of wheeze and 
dyspnea with childhood ETS exposure in smokers only is 
attributable to the earlier age of beginning smoking. How-
ever, it does not account for the earlier age of cough in the 
never-smokers. Multiple comparisons error is unlikely as 
childhood ETS exposure had a consistent effect on elevated 
risk of developing cough, mean age of onset of cough, and 
odds of currently having chronic cough.International Journal of COPD 2007:1(4) 491
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Personal smoking was associated with elevated risk 
of development of dyspnea beginning after 10 pack-years 
and increasing in a dose-dependent manner up to 30 pack-
years. Decreased risk after 30 pack-years might represent a 
“survivor effect” whereby those who are able to smoke that 
long without developing symptoms are less likely to do so 
in the future. Elevated risk for the development of cough 
and wheeze during the ﬁ  rst 10 pack-years of smoking only 
was not expected. It is possible that these represent irritant 
symptoms rather than true AAT deﬁ  ciency-related pulmonary 
injury and therefore might occur more quickly, if indeed 
they are to occur. Post-hoc analysis shows a median of ces-
sation of smoking 7 years after the development of cough, 4 
years after the development of wheeze, and 5 years after the 
development of dyspnea.
In order to achieve adequate statistical power, we re-
cruited study participants from four known populations with 
this uncommon disorder. As such, there is an inherent risk 
of selection bias that may limit our ability to generalize our 
ﬁ  ndings to the PI*Z population as a whole. Fewer subjects 
in this study reported dyspnea than in a survey of Alpha-1 
Association members (90% with dyspnea at mean age 48 
years) or participants in the National Heart, Lung, and Blood 
Institute Registry (90% at mean age 46 years). However, the 
prevalence of pulmonary symptoms was greater in our study 
population than in the Swedish Alpha-1 Registry studies 
(Piitulainen et al 1997, 1998). Our study subjects may have 
been more symptomatic than an unselected PI*Z population. 
Only a portion of the participant phenotypes were veriﬁ  ed. 
We believe that the possible inclusion of individuals with 
less severe deﬁ  ciency states, with their expected overall less 
severe clinical course, would have served only to decrease 
the power of our study.
Conclusion
In individuals with severe AAT deﬁ  ciency, personal smok-
ing was associated with earlier onset of cough, wheeze, and 
dyspnea. Self-reported childhood environmental tobacco 
smoke exposure was associated with younger age of cough. 
Childhood respiratory infections and family history of em-
physema were associated with earlier onset of wheeze.
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